A St. Louis-based company known for its work in Alzheimer's and neurological testing can expand its footprint, thanks to a $10 million investment from several life sciences companies.

C2N Diagnostics has received a $10m strategic investment out of Samsung’s life science investment fund. The US company said the cash injection would help to scale its clinical laboratory ...

C2N is currently expanding its biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry ...

As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...

C2N Diagnostics, LLC, a specialty diagnostics company, has received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment ...